Health & Biotech
Osteopore specialises in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing.
Osteopore is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgery use.
Osteopore products are made of a US FDA approved polymer called polycaprolactone (PCL). PCL is bioresorbable, malleable, slow-degrading and possesses mechanical strength similar to trabecular bone.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Stockhead TV
Break it Down: Osteopore seeking to raise $20 million
Health & Biotech
ASX health stocks capitalise on growing Southeast Asian market
News
Rise and Shine: Everything you need to know before the ASX opens
News
ASX Lunch Wrap: Shares on track for 10th straight gain, First Lithium soars, Megaport sinks 20pc
News
Market Highlights: Wall Street bulls are back after Fed minutes, and 5 ASX small caps to watch today
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: A very hot ASX banks on big banks after big central banks start cutting
News
ASX Small Caps Lunch Wrap: Who is really, definitely probably dead maybe this week?
News
Top 10 at 11: This morning is all about techies and goldies and bears, oh my!
News
Closing Bell: ASX clipped -1.3pc on broad selloff; BHP makes a $60bn play for Anglo American
News
ASX Small Caps and IPO Weekly Wrap: More downs than ups emerge from the latest 4-day week
News
ASX Small Caps Lunch Wrap: Who has unleashed the Flaming Hounds of Hell this week?
Health & Biotech
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Tech stocks in demand ahead of Tesla results; Osteopore up 130pc on clinical trial news
Health & Biotech
ASX Health Winners March: A rebound? Aussie biotech sector is on the radar of Asian investors
News